Literature DB >> 11226702

Changes in neuropeptide expression in the trigeminal ganglion following inferior alveolar nerve section in the ferret.

C Elcock1, F M Boissonade, P P Robinson.   

Abstract

Changes in neuropeptide expression in afferent nerve fibres may play a role in the persistent sensory abnormalities that can be experienced following trigeminal nerve injuries. We have therefore studied changes in the expression of the neuropeptides substance P, calcitonin gene-related peptide, enkephalin, galanin, neuropeptide Y and vasoactive intestinal polypeptide in the trigeminal ganglion following peripheral nerve injury. In anaesthetised adult female ferrets, the left inferior alveolar nerve was sectioned and recovery allowed for three days, three weeks or 12 weeks prior to perfusion-fixation. During a second procedure, one week prior to perfusion, the inferior alveolar nerve was exposed and an injection made central to the injury site using a mixture of 4 % Fluorogold and 4 % isolectin B4 conjugated to horseradish peroxidase to identify cell bodies with axons in the inferior alveolar nerve and cells with unmyelinated axons within this population, respectively. Control animals received tracer injection alone. After harvesting the tissue, sagittal sections were taken from both the right and left ganglia and immunohistochemical staining was used to reveal the presence of peptides and isolectin B4-horseradish peroxidase tracer. Within the Fluorogold-labelled population, cell counts revealed a significant reduction in the proportion of substance P-containing cells at three days (P = 0.0025), three weeks (P = 0.0094) and three months (P = 0.0149) after nerve section, and a significant reduction in the proportion of calcitonin gene-related peptide-containing cells at three days (P = 0.0003) and three weeks (P = 0.007). No significant changes were seen in the expression of the other peptides, or at other time periods. A significant reduction in the number of isolectin B4-horseradish peroxidase-positive cells (with unmyelinated axons) was seen at three days (P = 0.0025), three weeks (P = 0.0074) and three months after the injury (P = 0.0133). These results demonstrate a significant reduction in the expression of some neuropeptides in the early stages after inferior alveolar nerve section. Some of the results differ markedly from those reported previously in other systems, and may be related to the specific nerve studied, species variations or differences between spinal and trigeminal nerves.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226702     DOI: 10.1016/s0306-4522(00)00508-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Two types of neurotransmitter release patterns in isolectin B4-positive and negative trigeminal ganglion neurons.

Authors:  Y Matsuka; B Edmonds; S Mitrirattanakul; F E Schweizer; I Spigelman
Journal:  Neuroscience       Date:  2006-11-13       Impact factor: 3.590

2.  Neuronal plasticity of trigeminal ganglia in mice following nerve injury.

Authors:  Randi Lynds; Chuang Lyu; Gong-Wei Lyu; Xie-Qi Shi; Annika Rosén; Kamal Mustafa; Tie-Jun Sten Shi
Journal:  J Pain Res       Date:  2017-02-09       Impact factor: 3.133

Review 3.  Peripheral sympathetic mechanisms in orofacial pain.

Authors:  Wenguo Fan; Xiao Zhu; Yifan He; Hongmei Li; Wenzhen Gu; Fang Huang; Hongwen He
Journal:  J Pain Res       Date:  2018-10-17       Impact factor: 3.133

4.  In Situ Hybridisation Study of Neuronal Neuropeptides Expression in Models of Mandibular Denervation with or without Inflammation: Injury Dependant Neuropeptide Plasticity.

Authors:  Seham A Abd El-Aleem; Begonia M Morales-Aza
Journal:  J Cytol Histol       Date:  2018-06-29

5.  Correlation of miRNA expression with intensity of neuropathic pain in man.

Authors:  Diana Tavares-Ferreira; Nathan Lawless; Emma V Bird; Simon Atkins; David Collier; Emanuele Sher; Karim Malki; Daniel W Lambert; Fiona M Boissonade
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.